Treat‐To‐Target Goals for Atopic Dermatitis in Colombia: A Modified Delphi Consensus From the Colombian Group of Psoriasis and Immunodermatology ( COLPSOR )
Authors:
- Ángela María Londoño‐GarcíaÁLÁngela María Londoño‐García
- Juan Raúl Castro‐AyarzaJCJuan Raúl Castro‐Ayarza
- Manuel Darío Franco FrancoMFManuel Darío Franco Franco
- Paola Jimena Cárdenas RojasPRPaola Jimena Cárdenas Rojas
- Carolina Ivette Cortés CorreaCCCarolina Ivette Cortés Correa
- Natalia Montoya MorenoNMNatalia Montoya Moreno
- Liliana María Tamayo QuijanoLQLiliana María Tamayo Quijano
- Edison MoralesEMEdison Morales
- Esperanza María Meléndez RamírezEREsperanza María Meléndez Ramírez
- Ángela Seidel ArangoÁAÁngela Seidel Arango
- Luis Antonio Castro GómezLGLuis Antonio Castro Gómez
- Margarita María Velázquez LoperaMLMargarita María Velázquez Lopera
- 10 July 2026
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
Abstract
Atopic dermatitis causes substantial symptom burden and impaired quality of life. Treat‐to‐target strategies can improve care by linking management decisions to explicit therapeutic goals, but Colombia lacks a consensus framework for routine practice. We conducted a modified Delphi consensus with 22 Colombian specialists in atopic dermatitis. Two anonymous voting rounds were informed by a systematic literature review. Governance safeguards, conflict‐of‐interest management, and sponsor noninvolvement were prespecified. Main targets and timelines were classified with a simplified evidence‐level and recommendation‐strength framework. The panel defined acceptable and optimal therapeutic targets using clinician‐reported measures and patient‐reported outcome measures. Eczema Area and Severity Index (EASI)‐based thresholds and core symptom and quality‐of‐life instruments were supported by higher‐quality evidence, whereas follow‐up intervals, implementation strategies, and some adjunct measures relied more on expert consensus and contextual adaptation. The framework links response thresholds to reassessment timelines and treatment decisions for routine care. This consensus provides a practical treat‐to‐target framework for atopic dermatitis in Colombia and a model that may inform adaptation in other health systems. imageKeywords
Funding Information
- Pfizer
This publication has 34 references indexed in Scilit:
- Medidas de resultados comunicados por el paciente para evaluar la dermatitis atópicaFarmacia Hospitalaria, 2024
- Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendationsAnnals of Allergy, Asthma & Immunology, 2023
- Guidelines of care for the management of atopic dermatitis in adults with topical therapiesJournal of the American Academy of Dermatology, 2023
- Validity of the Hospital Anxiety and Depression Scale (HADS) in primary care patients in ColombiaGeneral Hospital Psychiatry, 2022
- Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiativeJournal of the American Academy of Dermatology, 2020
- Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2019
- Burden of skin pain in atopic dermatitisAnnals of Allergy, Asthma & Immunology, 2017
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014